Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Vertex Pharmaceutic (VRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 39,091,208
  • Shares Outstanding, K 252,120
  • Annual Sales, $ 1,702 M
  • Annual Income, $ -112,050 K
  • 36-Month Beta 1.73
  • Price/Sales 22.91
  • Price/Cash Flow 1,101.20
  • Price/Book 20.89

Price Performance

See More
Period Period Low Period High Performance
1-Month
147.30 +5.26%
on 09/27/17
157.78 -1.73%
on 10/16/17
+1.44 (+0.94%)
since 09/15/17
3-Month
127.67 +21.45%
on 07/18/17
167.85 -7.63%
on 07/25/17
+25.84 (+20.00%)
since 07/17/17
52-Week
71.46 +116.97%
on 12/22/16
167.85 -7.63%
on 07/25/17
+74.55 (+92.61%)
since 10/17/16

Most Recent Stories

More News
Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks

Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks

LGND : 142.15 (+0.29%)
CELG : 138.86 (+1.57%)
NVO : 49.31 (-0.02%)
VRTX : 155.05 (+0.23%)
NVS : 86.34 (-0.03%)
GILD : 80.24 (+0.36%)
PFE : 36.20 (+0.61%)
Vertex Announces 10-Year, $500 Million Corporate Giving Commitment

--Expands global efforts for providing patient and caregiver support including access to our medicines; developing young scientists and physicians; and strengthening our communities

VRTX : 155.05 (+0.23%)
Vertex to Announce Third Quarter 2017 Financial Results on October 25

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2017 financial results on Wednesday, October 25, 2017 after the financial markets close. The company...

VRTX : 155.05 (+0.23%)
Will Quest Diagnostics (DGX) Disappoint in Q3 Earnings?

The overall soft industry trends leading to low volume environment may continue to put a dampener on Quest Diagnostics (DGX) in Q3. The reimbursement scenario also remains a major cause for concern.

HUM : 240.43 (+1.37%)
COO : 235.98 (-0.41%)
DGX : 92.18 (+0.71%)
VRTX : 155.05 (+0.23%)
Vertex Pharmaceuticals, USG and J. Jill highlighted as Zacks Bull and Bear of the Day

Vertex Pharmaceuticals, USG and J. Jill highlighted as Zacks Bull and Bear of the Day

USG : 33.16 (+0.48%)
VRTX : 155.05 (+0.23%)
JILL : 4.82 (-1.63%)
Bull of the Day: Vertex Pharmaceuticals (VRTX)

Bull of the Day: Vertex Pharmaceuticals (VRTX)

VRTX : 155.05 (+0.23%)
Bull of the Day: Vertex Pharmaceuticals (VRTX)

Bull of the Day: Vertex Pharmaceuticals (VRTX)

VRTX : 155.05 (+0.23%)
Is a Beat in Store for Abbott (ABT) This Earnings Season?

Abbott's (ABT) FreeStyle Libre system receives back-to-back reimbursement approvals in several geographies, which are likely to drive growth in the Diabetes Care sales segment within Medical group.

HUM : 240.43 (+1.37%)
ABT : 55.06 (+0.79%)
VRTX : 155.05 (+0.23%)
QGEN : 34.26 (-0.75%)
Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit

With third quarter earnings round the corner, it was a relatively slow week with key updates including Regeneron (REGN) and partner Sanofi's win in the PCSK9 litigation.

CELG : 138.86 (+1.57%)
VRTX : 155.05 (+0.23%)
CLVS : 81.32 (-3.85%)
ABBV : 92.17 (+1.24%)
REGN : 442.56 (-0.70%)
AMGN : 186.19 (+2.36%)
BIIB : 344.47 (+2.62%)
Amgen Label Expansion Application for Prolia Accepted by FDA

Amgen (AMGN) announced that the FDA has accepted its regulatory application in the U.S. seeking label expansion for Prolia for treating patients with glucocorticoid-induced osteoporosis (GIOP).

CELG : 138.86 (+1.57%)
PDLI : 3.45 (-1.71%)
VRTX : 155.05 (+0.23%)
AMGN : 186.19 (+2.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Vertex Pharmaceuticals Inc. discovers, develops and markets small molecule drugs that address major unmet medical needs. The company has eight drug candidates in clinical development to treat viral diseases, inflammation, cancer, autoimmune diseases and neurological disorders. Vertex has created its...

See More

Support & Resistance

2nd Resistance Point 157.00
1st Resistance Point 156.03
Last Price 155.05
1st Support Level 154.05
2nd Support Level 153.04

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart